कंपनी का अवलोकन
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical entity dedicated to the development and commercialization of seralutinib, a therapeutic agent targeting pulmonary hypertension and pulmonary arterial hypertension within the United States market. The company operates within the Healthcare sector, specifically functioning in the Biotechnology industry, which implies a focus on high-risk, high-reward research and development activities aimed at addressing unmet medical needs. As of the latest reporting period, the organization employs 161 individuals and holds a market capitalization of $87.21M, generating annual revenue of $48.47M in the trailing twelve months. These financial figures indicate that Gossamer Bio operates with a relatively small market capitalization compared to large-cap pharmaceutical peers, reflecting its stage of development where significant value is derived from potential future product approvals rather than established sales volume.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $48.47M alongside a net income of $-170,370,000 and an EBITDA of $-163,228,992, revealing a substantial gap between top-line generation and bottom-line profitability that points to a heavy cost structure driven by research, development, and clinical trial expenses. Free cash flow stands at $-93,332,248, which signifies that the company is currently burning cash to fund its operations and pipeline advancement, thereby limiting immediate financial flexibility without external capital raises or asset monetization. The margin profile presents a gross margin of 100.0%, indicating that the cost of goods sold is negligible relative to revenue, contrasted by an operating margin of -333.6% and a profit margin of 0.0% which together illustrate that operational expenses and R&D costs are consuming the entire revenue stream. On the liability side, the company holds $136.93M in cash against $202.91M in debt, resulting in a debt-to-equity ratio marked as N/A due to equity constraints, suggesting a leveraged balance sheet where cash reserves are insufficient to fully cover total indebtedness. Short-term liquidity is supported by a current ratio of 2.64, indicating that current assets are more than double current liabilities and providing a buffer against immediate solvency pressures. Return on Equity and Return on Assets metrics are listed as N/A and -41.9% respectively, with the negative return on assets highlighting that the asset base is generating a loss relative to its total value, reflecting the capital-intensive nature of the clinical-stage business model.
मूल्यांकन आकलन
Valuation metrics for Gossamer Bio reflect its pre-profitability status, with a trailing P/E ratio of N/A and a forward P/E of -2.23, implying that traditional earnings-based valuation models are not applicable and that future earnings expectations are currently negative or undefined. The price-to-book ratio is recorded at -0.71, which indicates that the market values the company at a negative premium relative to its book value, a common characteristic for biotech firms with significant intangible assets or R&D investments not fully captured on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 1.80 and an EV/EBITDA of -0.94 suggest that investors are pricing the stock based on revenue potential and enterprise value relative to earnings power rather than current profitability. Price momentum indicators show a 52-week high of $3.87 and a 52-week low of $0.32, providing a range within which the stock has traded over the past year to assess relative positioning. The stock exhibits a beta of 2.16, meaning it is expected to be significantly more volatile than the broader market, with price movements typically amplified by approximately 116% of market swings.
Growth & Income
Revenue growth year-over-year stands at 47.1%, demonstrating a robust expansion in sales, while earnings growth is N/A due to the company's continued net losses, indicating that revenue expansion has not yet translated into profitability. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which implies that all available earnings or cash flow are retained within the company to fund ongoing research and development efforts rather than being distributed to shareholders. This reinvestment strategy is typical for clinical-stage biotechnology companies where capital must be deployed to advance drug candidates through clinical trials to achieve regulatory approval. Overall, the growth and income profile is characterized by strong revenue acceleration and zero dividend distribution, focusing entirely on capital preservation and pipeline development to potentially transition into a profitable state in the future.